$REGN Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in REGENERON PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in REGENERON PHARMACEUTICALS, INC.. Get notifications about new insider transactions in REGENERON PHARMACEUTICALS, INC. for free.
Page: < prev 1 ... 6 7 8 9 10 11 12 13 14 ... 48 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 14 2018 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Gift | G | 0.00 | 2,950 | 0 | 2,950 | 0 to 3 K |
| Dec 14 2018 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Gift | G | 0.00 | 2,950 | 0 | 1,397 | 4.3 K to 1.4 K (-67.86 %) |
| Dec 14 2018 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Gift | G | 0.00 | 50 | 0 | 4,347 | 4.3 K to 4.3 K (+1.16 %) |
| Dec 14 2018 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Grant | A | 0.00 | 5,000 | 0 | 6,421 | 1.4 K to 6.4 K (+351.86 %) |
| Dec 14 2018 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Gift | G | 0.00 | 50 | 0 | 1,421 | 1.5 K to 1.4 K (-3.40 %) |
| Dec 14 2018 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | SVP General Counsel ... | Option Exercise | A | 381.40 | 20,000 | 7,628,000 | 20,000 | |
| Dec 14 2018 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Option Exercise | A | 381.40 | 20,000 | 7,628,000 | 20,000 | |
| Dec 14 2018 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Grant | A | 0.00 | 12,500 | 0 | 17,348 | 4.8 K to 17.3 K (+257.84 %) |
| Dec 14 2018 | REGN | REGENERON PHARMACE ... | McCourt Marion | SVP Commercial | Option Exercise | A | 381.40 | 10,000 | 3,814,000 | 10,000 | |
| Dec 14 2018 | REGN | REGENERON PHARMACE ... | McCourt Marion | SVP Commercial | Grant | A | 0.00 | 10,000 | 0 | 12,500 | 2.5 K to 12.5 K (+400.00 %) |
| Dec 14 2018 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Option Exercise | A | 381.40 | 20,000 | 7,628,000 | 20,000 | |
| Dec 14 2018 | REGN | REGENERON PHARMACE ... | Van Plew Daniel P | EVP & General Mgr I ... | Option Exercise | A | 381.40 | 46,250 | 17,639,750 | 46,250 | |
| Sep 28 2018 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Option Exercise | M | 273.67 | 2,000 | 547,340 | 10,750 | |
| Sep 28 2018 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Sell | S | 395.42 | 260 | 102,809 | 0 | 260 to 0 (-100.00 %) |
| Sep 28 2018 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Sell | S | 394.43 | 40 | 15,777 | 260 | 300 to 260 (-13.33 %) |
| Sep 28 2018 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Sell | S | 393.49 | 300 | 118,047 | 300 | 600 to 300 (-50.00 %) |
| Sep 28 2018 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Sell | S | 392.37 | 410 | 160,872 | 600 | 1 K to 600 (-40.59 %) |
| Sep 28 2018 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Sell | S | 391.38 | 601 | 235,219 | 1,010 | 1.6 K to 1 K (-37.31 %) |
| Sep 28 2018 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Sell | S | 390.23 | 389 | 151,799 | 1,611 | 2 K to 1.6 K (-19.45 %) |
| Sep 28 2018 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Buy | M | 273.67 | 2,000 | 547,340 | 2,000 | 0 to 2 K |
| Sep 25 2018 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Option Exercise | M | 273.67 | 1,000 | 273,670 | 4,500 | |
| Sep 25 2018 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Option Exercise | M | 273.67 | 1,000 | 273,670 | 5,500 | |
| Sep 25 2018 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Sell | S | 387.29 | 1,000 | 387,290 | 12,000 | 13 K to 12 K (-7.69 %) |
| Sep 25 2018 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Buy | M | 273.67 | 1,000 | 273,670 | 13,000 | 12 K to 13 K (+8.33 %) |
| Sep 25 2018 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Sell | S | 390.00 | 1,000 | 390,000 | 12,000 | 13 K to 12 K (-7.69 %) |
| Sep 25 2018 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Buy | M | 273.67 | 1,000 | 273,670 | 13,000 | 12 K to 13 K (+8.33 %) |
| Sep 11 2018 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Payment of Exercise | F | 395.29 | 2,251 | 889,798 | 4,848 | 7.1 K to 4.8 K (-31.71 %) |
| Sep 10 2018 | REGN | REGENERON PHARMACE ... | Sanofi | Sell | S | 406.68 | 104,552 | 42,519,249 | 23,654,384 | 23.8 M to 23.7 M (-0.44 %) | |
| Aug 31 2018 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Option Exercise | M | 21.25 | 50 | 1,063 | 1,175 | |
| Aug 31 2018 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Buy | M | 21.25 | 50 | 1,063 | 200 | 150 to 200 (+33.33 %) |
| Aug 23 2018 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Option Exercise | M | 177.82 | 1,500 | 266,730 | 0 | |
| Aug 23 2018 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Gift | G | 0.00 | 5,000 | 0 | 12,349 | 17.3 K to 12.3 K (-28.82 %) |
| Aug 23 2018 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Gift | G | 0.00 | 5,000 | 0 | 5,000 | 0 to 5 K |
| Aug 23 2018 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Sell | S | 380.49 | 1,500 | 570,735 | 0 | 1.5 K to 0 (-100.00 %) |
| Aug 23 2018 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Buy | M | 177.82 | 1,500 | 266,730 | 1,500 | 0 to 1.5 K |
| Aug 21 2018 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Option Exercise | M | 21.25 | 210 | 4,463 | 307,585 | |
| Aug 21 2018 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Payment of Exercise | F | 374.46 | 108 | 40,442 | 399,949 | 400.1 K to 399.9 K (-0.03 %) |
| Aug 21 2018 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Buy | M | 21.25 | 210 | 4,463 | 400,057 | 399.8 K to 400.1 K (+0.05 %) |
| Aug 03 2018 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Option Exercise | M | 57.11 | 2,000 | 114,220 | 0 | |
| Aug 03 2018 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Sell | S | 380.00 | 2,000 | 760,000 | 12,000 | 14 K to 12 K (-14.29 %) |
| Aug 03 2018 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Buy | M | 57.11 | 2,000 | 114,220 | 14,000 | 12 K to 14 K (+16.67 %) |
| Jul 11 2018 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Option Exercise | M | 16.80 | 153,274 | 2,575,003 | 0 | |
| Jul 11 2018 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Gift | G | 0.00 | 610 | 0 | 147,934 | 148.5 K to 147.9 K (-0.41 %) |
| Jul 11 2018 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Sell | S | 371.29 | 300 | 111,387 | 399,847 | 400.1 K to 399.8 K (-0.07 %) |
| Jul 11 2018 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Sell | S | 370.17 | 100 | 37,017 | 400,147 | 400.2 K to 400.1 K (-0.02 %) |
| Jul 11 2018 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Sell | S | 369.41 | 13,194 | 4,873,996 | 400,247 | 413.4 K to 400.2 K (-3.19 %) |
| Jul 11 2018 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Sell | S | 368.61 | 12,211 | 4,501,097 | 413,441 | 425.7 K to 413.4 K (-2.87 %) |
| Jul 11 2018 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Sell | S | 367.40 | 6,405 | 2,353,197 | 425,652 | 432.1 K to 425.7 K (-1.48 %) |
| Jul 11 2018 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Sell | S | 366.49 | 24,339 | 8,920,000 | 432,057 | 456.4 K to 432.1 K (-5.33 %) |
| Jul 11 2018 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Sell | S | 365.56 | 17,221 | 6,295,309 | 456,396 | 473.6 K to 456.4 K (-3.64 %) |
| Jul 11 2018 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Sell | S | 364.75 | 900 | 328,275 | 473,617 | 474.5 K to 473.6 K (-0.19 %) |
| Jul 11 2018 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Payment of Exercise | F | 370.52 | 78,604 | 29,124,354 | 474,517 | 553.1 K to 474.5 K (-14.21 %) |
| Jul 11 2018 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Buy | M | 16.80 | 153,274 | 2,575,003 | 553,121 | 399.8 K to 553.1 K (+38.33 %) |
| Jul 09 2018 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Option Exercise | M | 57.11 | 2,000 | 114,220 | 2,000 | |
| Jul 09 2018 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Option Exercise | M | 57.11 | 2,000 | 114,220 | 4,000 | |
| Jul 09 2018 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Sell | S | 370.00 | 2,000 | 740,000 | 12,000 | 14 K to 12 K (-14.29 %) |
| Jul 09 2018 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Buy | M | 57.11 | 2,000 | 114,220 | 14,000 | 12 K to 14 K (+16.67 %) |
| Jul 09 2018 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Sell | S | 360.00 | 2,000 | 720,000 | 12,000 | 14 K to 12 K (-14.29 %) |
| Jul 09 2018 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Buy | M | 57.11 | 2,000 | 114,220 | 14,000 | 12 K to 14 K (+16.67 %) |
| Jun 22 2018 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Option Exercise | M | 16.80 | 153,274 | 2,575,003 | 153,274 | |
| Jun 22 2018 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Gift | G | 0.00 | 616 | 0 | 148,544 | 149.2 K to 148.5 K (-0.41 %) |
| Jun 22 2018 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Gift | G | 0.00 | 557 | 0 | 149,160 | 149.7 K to 149.2 K (-0.37 %) |
| Jun 22 2018 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Sell | S | 336.87 | 200 | 67,374 | 399,847 | 400 K to 399.8 K (-0.05 %) |
| Jun 22 2018 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Sell | S | 335.01 | 300 | 100,503 | 400,047 | 400.3 K to 400 K (-0.07 %) |
| Jun 22 2018 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Sell | S | 333.15 | 500 | 166,575 | 400,347 | 400.8 K to 400.3 K (-0.12 %) |
| Jun 22 2018 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Sell | S | 332.80 | 1,300 | 432,640 | 400,847 | 402.1 K to 400.8 K (-0.32 %) |
| Jun 22 2018 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Sell | S | 331.09 | 100 | 33,109 | 402,147 | 402.2 K to 402.1 K (-0.02 %) |
| Jun 22 2018 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Sell | S | 330.32 | 3,096 | 1,022,671 | 402,247 | 405.3 K to 402.2 K (-0.76 %) |
| Jun 22 2018 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Sell | S | 329.51 | 12,854 | 4,235,522 | 405,343 | 418.2 K to 405.3 K (-3.07 %) |
| Jun 22 2018 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Sell | S | 328.45 | 12,426 | 4,081,320 | 418,197 | 430.6 K to 418.2 K (-2.89 %) |
| Jun 22 2018 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Sell | S | 327.48 | 19,393 | 6,350,820 | 430,623 | 450 K to 430.6 K (-4.31 %) |
| Jun 22 2018 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Sell | S | 326.57 | 15,594 | 5,092,533 | 450,016 | 465.6 K to 450 K (-3.35 %) |
| Jun 22 2018 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Sell | S | 325.67 | 8,047 | 2,620,666 | 465,610 | 473.7 K to 465.6 K (-1.70 %) |
| Jun 22 2018 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Sell | S | 324.18 | 500 | 162,090 | 473,657 | 474.2 K to 473.7 K (-0.11 %) |
| Jun 22 2018 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Sell | S | 323.97 | 400 | 129,588 | 474,157 | 474.6 K to 474.2 K (-0.08 %) |
| Jun 22 2018 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Payment of Exercise | F | 333.07 | 78,564 | 26,167,311 | 474,557 | 553.1 K to 474.6 K (-14.20 %) |
| Jun 22 2018 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Buy | M | 16.80 | 153,274 | 2,575,003 | 553,121 | 399.8 K to 553.1 K (+38.33 %) |
| Jun 11 2018 | REGN | REGENERON PHARMACE ... | Sanofi | Sell | S | 309.31 | 121,601 | 37,611,882 | 23,758,936 | 23.9 M to 23.8 M (-0.51 %) | |
| May 25 2018 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Option Exercise | M | 30.63 | 26,736 | 818,924 | 0 | |
| May 25 2018 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 295.09 | 11,407 | 3,366,092 | 31,973 | 43.4 K to 32 K (-26.30 %) |
| May 25 2018 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Payment of Exercise | F | 293.68 | 15,329 | 4,501,821 | 43,380 | 58.7 K to 43.4 K (-26.11 %) |
| May 25 2018 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Buy | M | 30.63 | 26,736 | 818,924 | 58,709 | 32 K to 58.7 K (+83.62 %) |
| May 11 2018 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Sell | S | 288.00 | 4,000 | 1,152,000 | 114,772 | 118.8 K to 114.8 K (-3.37 %) |
| May 11 2018 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Sell | S | 287.00 | 3,000 | 861,000 | 118,772 | 121.8 K to 118.8 K (-2.46 %) |
| May 11 2018 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Sell | S | 286.00 | 3,000 | 858,000 | 121,772 | 124.8 K to 121.8 K (-2.40 %) |
| May 11 2018 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Sell | S | 285.00 | 3,000 | 855,000 | 124,772 | 127.8 K to 124.8 K (-2.35 %) |
| May 11 2018 | REGN | REGENERON PHARMACE ... | SING GEORGE L | Director | Sell | S | 285.29 | 7,000 | 1,997,030 | 127,772 | 134.8 K to 127.8 K (-5.19 %) |
| Mar 19 2018 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Option Exercise | M | 57.11 | 2,000 | 114,220 | 6,000 | |
| Mar 19 2018 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Sell | S | 350.02 | 2,000 | 700,040 | 12,000 | 14 K to 12 K (-14.29 %) |
| Mar 19 2018 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Buy | M | 57.11 | 2,000 | 114,220 | 14,000 | 12 K to 14 K (+16.67 %) |
| Mar 14 2018 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Option Exercise | M | 57.11 | 2,000 | 114,220 | 8,000 | |
| Mar 14 2018 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Sell | S | 340.00 | 2,000 | 680,000 | 12,000 | 14 K to 12 K (-14.29 %) |
| Mar 14 2018 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Buy | M | 57.11 | 2,000 | 114,220 | 14,000 | 12 K to 14 K (+16.67 %) |
| Feb 13 2018 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Sell | S | 325.60 | 1,000 | 325,600 | 12,000 | 13 K to 12 K (-7.69 %) |
| Feb 12 2018 | REGN | REGENERON PHARMACE ... | McCourt Marion | SVP Commercial | Option Exercise | A | 342.93 | 20,000 | 6,858,600 | 20,000 | |
| Feb 12 2018 | REGN | REGENERON PHARMACE ... | McCourt Marion | SVP Commercial | Grant | A | 0.00 | 2,500 | 0 | 2,500 | 0 to 2.5 K |
| Jan 17 2018 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Option Exercise | M | 21.25 | 150 | 3,188 | 1,225 | |
| Jan 17 2018 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Buy | M | 21.25 | 150 | 3,188 | 150 | 0 to 150 |
| Jan 04 2018 | REGN | REGENERON PHARMACE ... | COLES N ANTHONY | Director | Option Exercise | A | 380.95 | 6,909 | 2,631,984 | 6,909 | |
| Jan 03 2018 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Option Exercise | A | 380.95 | 7,439 | 2,833,887 | 7,439 | |
| Jan 03 2018 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Option Exercise | A | 380.95 | 7,439 | 2,833,887 | 7,439 | |
| Jan 03 2018 | REGN | REGENERON PHARMACE ... | POON CHRISTINE A | Director | Option Exercise | A | 380.95 | 7,439 | 2,833,887 | 7,439 | |
| Dec 20 2017 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President & CSO | Payment of Exercise | F | 386.90 | 257,850 | 99,762,165 | 422,762 | 680.6 K to 422.8 K (-37.89 %) |
| Dec 13 2017 | REGN | REGENERON PHARMACE ... | SCHLEIFER LEONARD S | President & CEO | Option Exercise | A | 378.98 | 139,474 | 52,857,857 | 139,474 | |
| Dec 13 2017 | REGN | REGENERON PHARMACE ... | SCHLEIFER LEONARD S | President & CEO | Option Exercise | M | 21.92 | 250,000 | 5,480,000 | 0 | |
| Dec 13 2017 | REGN | REGENERON PHARMACE ... | SCHLEIFER LEONARD S | President & CEO | Payment of Exercise | F | 385.08 | 121,586 | 46,820,337 | 271,593 | 393.2 K to 271.6 K (-30.92 %) |
| Dec 13 2017 | REGN | REGENERON PHARMACE ... | SCHLEIFER LEONARD S | President & CEO | Payment of Exercise | F | 385.08 | 14,230 | 5,479,688 | 393,179 | 407.4 K to 393.2 K (-3.49 %) |
| Dec 13 2017 | REGN | REGENERON PHARMACE ... | SCHLEIFER LEONARD S | President & CEO | Buy | M | 21.92 | 250,000 | 5,480,000 | 407,409 | 157.4 K to 407.4 K (+158.82 %) |
| Dec 13 2017 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President & CSO | Option Exercise | A | 378.98 | 139,474 | 52,857,857 | 139,474 | |
| Dec 13 2017 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President & CSO | Option Exercise | M | 21.92 | 195,438 | 4,284,001 | 0 | |
| Dec 13 2017 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President & CSO | Payment of Exercise | F | 385.08 | 95,050 | 36,601,854 | 680,612 | 775.7 K to 680.6 K (-12.25 %) |
| Dec 13 2017 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President & CSO | Payment of Exercise | F | 385.08 | 11,124 | 4,283,630 | 775,662 | 786.8 K to 775.7 K (-1.41 %) |
| Dec 13 2017 | REGN | REGENERON PHARMACE ... | YANCOPOULOS GEORGE | President & CSO | Buy | M | 21.92 | 195,438 | 4,284,001 | 786,786 | 591.3 K to 786.8 K (+33.05 %) |
| Dec 13 2017 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | SVP General Counsel ... | Option Exercise | A | 378.98 | 23,337 | 8,844,256 | 23,337 | |
| Dec 13 2017 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Option Exercise | A | 378.98 | 12,300 | 4,661,454 | 12,300 | |
| Dec 13 2017 | REGN | REGENERON PHARMACE ... | Van Plew Daniel P | EVP & General Mgr I ... | Option Exercise | A | 378.98 | 50,000 | 18,949,000 | 50,000 | |
| Dec 13 2017 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Option Exercise | A | 378.98 | 74,390 | 28,192,322 | 74,390 | |
| Dec 13 2017 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Option Exercise | M | 21.92 | 153,969 | 3,375,000 | 0 | |
| Dec 13 2017 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Gift | G | 0.00 | 91 | 0 | 149,717 | 149.8 K to 149.7 K (-0.06 %) |
| Dec 13 2017 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Gift | G | 0.00 | 477 | 0 | 149,808 | 150.3 K to 149.8 K (-0.32 %) |
| Dec 13 2017 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Payment of Exercise | F | 383.29 | 74,860 | 28,693,089 | 399,847 | 474.7 K to 399.8 K (-15.77 %) |
| Dec 13 2017 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Payment of Exercise | F | 383.29 | 8,805 | 3,374,868 | 474,707 | 483.5 K to 474.7 K (-1.82 %) |
| Dec 13 2017 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Chairman of the Boa ... | Buy | M | 21.92 | 153,969 | 3,375,000 | 483,512 | 329.5 K to 483.5 K (+46.72 %) |
| Dec 13 2017 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Option Exercise | A | 378.98 | 50,000 | 18,949,000 | 50,000 | |
| Dec 13 2017 | REGN | REGENERON PHARMACE ... | Terifay Robert J | EVP Commercial | Option Exercise | A | 378.98 | 32,300 | 12,241,054 | 32,300 | |
| Dec 13 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Option Exercise | A | 378.98 | 23,337 | 8,844,256 | 23,337 | |
| Oct 05 2017 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Option Exercise | M | 177.82 | 1,500 | 266,730 | 1,500 | |
| Oct 05 2017 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Sell | S | 475.00 | 1,500 | 712,500 | 0 | 1.5 K to 0 (-100.00 %) |
| Oct 05 2017 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Buy | M | 177.82 | 1,500 | 266,730 | 1,500 | 0 to 1.5 K |
| Oct 03 2017 | REGN | REGENERON PHARMACE ... | BAKER CHARLES A | Director | Option Exercise | M | 18.61 | 2,000 | 37,220 | 0 | |
| Oct 03 2017 | REGN | REGENERON PHARMACE ... | BAKER CHARLES A | Director | Sell | S | 450.00 | 2,000 | 900,000 | 9,000 | 11 K to 9 K (-18.18 %) |
| Oct 03 2017 | REGN | REGENERON PHARMACE ... | BAKER CHARLES A | Director | Buy | M | 18.61 | 2,000 | 37,220 | 11,000 | 9 K to 11 K (+22.22 %) |
| Sep 06 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Option Exercise | M | 272.70 | 3,000 | 818,100 | 57,000 | |
| Sep 06 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Sell | S | 499.69 | 100 | 49,969 | 7,099 | 7.2 K to 7.1 K (-1.39 %) |
| Sep 06 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Sell | S | 498.25 | 100 | 49,825 | 7,199 | 7.3 K to 7.2 K (-1.37 %) |
| Sep 06 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Sell | S | 496.86 | 100 | 49,686 | 7,299 | 7.4 K to 7.3 K (-1.35 %) |
| Sep 06 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Sell | S | 496.52 | 74 | 36,742 | 7,399 | 7.5 K to 7.4 K (-0.99 %) |
| Sep 06 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Sell | S | 496.51 | 100 | 49,651 | 7,473 | 7.6 K to 7.5 K (-1.32 %) |
| Sep 06 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Sell | S | 501.88 | 89 | 44,667 | 7,573 | 7.7 K to 7.6 K (-1.16 %) |
| Sep 06 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Sell | S | 500.33 | 100 | 50,033 | 7,662 | 7.8 K to 7.7 K (-1.29 %) |
| Sep 06 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Payment of Exercise | F | 501.29 | 706 | 353,911 | 7,762 | 8.5 K to 7.8 K (-8.34 %) |
| Sep 06 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Payment of Exercise | F | 501.29 | 1,631 | 817,604 | 8,468 | 10.1 K to 8.5 K (-16.15 %) |
| Sep 06 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Buy | M | 272.70 | 3,000 | 818,100 | 10,099 | 7.1 K to 10.1 K (+42.26 %) |
| Sep 01 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Option Exercise | M | 272.70 | 2,000 | 545,400 | 60,000 | |
| Sep 01 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Sell | S | 497.69 | 127 | 63,207 | 7,099 | 7.2 K to 7.1 K (-1.76 %) |
| Sep 01 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Sell | S | 497.42 | 100 | 49,742 | 7,226 | 7.3 K to 7.2 K (-1.37 %) |
| Sep 01 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Sell | S | 489.56 | 100 | 48,956 | 7,326 | 7.4 K to 7.3 K (-1.35 %) |
| Sep 01 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Sell | S | 487.88 | 100 | 48,788 | 7,426 | 7.5 K to 7.4 K (-1.33 %) |
| Sep 01 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Payment of Exercise | F | 486.91 | 454 | 221,057 | 7,526 | 8 K to 7.5 K (-5.69 %) |
| Sep 01 2017 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Payment of Exercise | F | 486.91 | 1,119 | 544,852 | 7,980 | 9.1 K to 8 K (-12.30 %) |